Time point |  − 100–0 Cohort baseline | 0 TwiC baseline | 150–240 6-month follow-up | 300–420 12-month follow-up |
---|---|---|---|---|
ComBaCaL cohort activities | ||||
 ComBaCaL cohort informed consenta | X |  |  |  |
 Date of birth | X |  |  |  |
 Height, weight, abdominal circumference | X |  | X | X |
 Short medical historyb | X |  |  |  |
 CVDRFsc | X |  | X | X |
 T2D Screeningd | X |  |  |  |
TwiC assessments | ||||
 FBG |  | X | X | X |
 HbA1c |  | X | X | X |
 Diabetes distresse |  |  | X | X |
 Health beliefsf |  | X |  | X |
 Quality of lifeg |  | X | X | X |
 Self-reported access to care and to medication |  | X | X | X |
 Blood lipid statush |  | X | X | X |
 Current antidiabetic and lipid-lowering medication | X | X | X | X |
 Adherence to antidiabetic medication |  | X | X | X |
 Screening for relevant clinical events |  | X | X | X |
 Screening for clinical alarm signs/symptoms |  | X | X | X |
TwiC control | ||||
 Referral to health facility if required |  | X | X | X |
TwiC intervention | ||||
 Offer metformini |  | X | X | X |
 Offer lipid-lowering treatmenti |  | X | X | X |
 Provide lifestyle counselling |  | X | X | X |
 Provide treatment supportj |  | X | X | X |
 Referral to health facilityk |  | X | X | X |